Form 4 holding
Director, Other*
Kymera Therapeutics, Inc.
- Security class
- Common Stock, $0.0001 par value
- Shares / value
- 240,123
- Estimated value
- $25,573,099
- Report date
- 26 Jun 2026
- Price
- $106.50
- Ownership
- Direct
BVF PARTNERS L P/IL
Insider Reports History
- Reporting-owner location
- San Francisco, CA
- Latest reporting-owner signature
-
BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for BVF PARTNERS L P/IL
Form 4 holding
Director, 10%+ Owner
MoonLake Immunotherapeutics
- Security class
- Class A Ordinary Shares, $0.0001 par value
- Shares / value
- 1,039,238
- Estimated value
- $19,371,396
- Report date
- 17 Jun 2026
- Price
- $18.64
- Ownership
- Direct
Form 4 holding
10%+ Owner
XOMA Royalty Corp
- Security class
- Series X Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- $18,998,920
- Report date
- 14 May 2026
- Price
- $24610.00
- Ownership
- Indirect
- Underlying class
- Common Stock, $0.0075 par value per share
- Underlying amount
- 772,000
Form 4 holding
10%+ Owner
Verastem, Inc.
- Security class
- Common Stock
- Shares / value
- 994,353
- Estimated value
- $10,888,165
- Report date
- 25 Jan 2022
- Price
- $10.95
- Ownership
- Direct
Form 4 holding
10%+ Owner
XOMA Royalty Corp
- Security class
- Series X Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- $10,139,320
- Report date
- 14 May 2026
- Price
- $24610.00
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0075 par value per share
- Underlying amount
- 412,000
Form 4 holding
Director, Other*
Kymera Therapeutics, Inc.
- Security class
- Common Stock, $0.0001 par value
- Shares / value
- 78,787
- Estimated value
- $8,390,815
- Report date
- 26 Jun 2026
- Price
- $106.50
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Merus N.V.
- Security class
- Common Shares, (euro)0.09 nominal value per share
- Shares / value
- 232,747
- Estimated value
- $6,467,225
- Report date
- 08 Oct 2021
- Price
- $27.79
- Ownership
- Direct
Form 4 holding
Director, Other*
Olema Pharmaceuticals, Inc.
- Security class
- Common stock, $0.0001 par value
- Shares / value
- 347,970
- Estimated value
- $5,188,232
- Report date
- 18 Jun 2026
- Price
- $14.91
- Ownership
- Direct
Form 4 holding
Director, Other*
Olema Pharmaceuticals, Inc.
- Security class
- Pre-Funded Warrant
- Shares / value
- 336,288
- Estimated value
- $4,728,209
- Report date
- 18 Jun 2026
- Price
- $14.06
- Ownership
- Direct
- Underlying class
- Common stock, $0.0001 par value
- Underlying amount
- 336,288
Form 4 holding
Director, Other*
Kymera Therapeutics, Inc.
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 52,733
- Estimated value
- $4,308,286
- Report date
- 26 Jun 2026
- Price
- $81.70
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 52,733
Form 4 holding
10%+ Owner
Eledon Pharmaceuticals, Inc.
- Security class
- Pre-funded Warrants to Purchase Common Stock
- Shares / value
- 838,507
- Estimated value
- $3,059,712
- Report date
- 29 Oct 2024
- Price
- $3.65
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
Form 4 holding
Other*
Third Harmonic Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 176,692
- Estimated value
- $2,526,696
- Report date
- 29 Oct 2024
- Price
- $14.30
- Ownership
- Direct
Form 4 holding
Director, Other*
Kymera Therapeutics, Inc.
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 27,797
- Estimated value
- $2,271,014
- Report date
- 26 Jun 2026
- Price
- $81.70
- Ownership
- Indirect
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 27,797
Form 4 holding
Director, Other*
Olema Pharmaceuticals, Inc.
- Security class
- Common stock, $0.0001 par value
- Shares / value
- 99,556
- Estimated value
- $1,484,379
- Report date
- 18 Jun 2026
- Price
- $14.91
- Ownership
- Indirect
Form 4 holding
Other*
4D Molecular Therapeutics, Inc.
- Security class
- Common Stock, $0.0001 par value
- Shares / value
- 87,911
- Estimated value
- $1,435,587
- Report date
- 08 Nov 2024
- Price
- $16.33
- Ownership
- Direct
Form 4 holding
10%+ Owner
Eledon Pharmaceuticals, Inc.
- Security class
- Common Stock, $0.001 par value
- Shares / value
- 220,460
- Estimated value
- $987,661
- Report date
- 29 Oct 2024
- Price
- $4.48
- Ownership
- Direct
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 64,161
- Estimated value
- $799,446
- Report date
- 19 Jan 2023
- Price
- $12.46
- Ownership
- Direct
Form 4 holding
Other*
PIERIS PHARMACEUTICALS, INC.
- Security class
- Common Stock, $0.001 par value
- Shares / value
- 38,961
- Estimated value
- $618,794
- Report date
- 13 Dec 2024
- Price
- $15.88
- Ownership
- Direct
Form 4 holding
Director, Other*
Kymera Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 6,068
- Estimated value
- $495,755
- Report date
- 26 Jun 2026
- Price
- $81.70
- Ownership
- Indirect
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 6,068
Form 4 holding
Director, Other*
Olema Pharmaceuticals, Inc.
- Security class
- Stock Option (Right to buy)
- Shares / value
- 29,500
- Estimated value
- $414,770
- Report date
- 18 Jun 2026
- Price
- $14.06
- Ownership
- Indirect
- Underlying class
- Common stock, $0.0001 par value
- Underlying amount
- 29,500
Form 4 holding
Director, 10%+ Owner
MoonLake Immunotherapeutics
- Security class
- Option to Buy
- Shares / value
- 22,195
- Estimated value
- $414,602
- Report date
- 17 Jun 2026
- Price
- $18.68
- Ownership
- Indirect
- Underlying class
- Class A Ordinary Shares, $0.0001 par value
- Underlying amount
- 22,195
Form 4 holding
Director, Other*
IMMUNIC, INC.
- Security class
- Common Stock, $0.0001 par value
- Shares / value
- 427,629
- Estimated value
- $260,853
- Report date
- 17 Feb 2026
- Price
- $0.6100
- Ownership
- Direct
Form 4 holding
10%+ Owner
GLYCOMIMETICS INC
- Security class
- Common Stock
- Shares / value
- 62,383
- Estimated value
- $13,100
- Report date
- 13 Jun 2025
- Price
- $0.2100
- Ownership
- Direct
Form 4 holding
10%+ Owner
Allakos Inc.
- Security class
- Common Stock, $0.001 par value
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 15 May 2025
- Price
- $0.3200
- Ownership
- Direct
Form 4 holding
10%+ Owner
ESSA Pharma Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 09 Oct 2025
- Price
- $0.2400
- Ownership
- Direct
Form 4 holding
Director, Other*
Rain Oncology Inc.
- Security class
- Common Stock, $0.001 par value
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 25 Jan 2024
- Price
- $1.21
- Ownership
- Direct
Form 4 holding
10%+ Owner
Repare Therapeutics Inc.
- Security class
- Common Shares, no par value
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 28 Jan 2026
- Price
- $2.60
- Ownership
- Direct
Form 4 holding
10%+ Owner
XOMA Royalty Corp
- Security class
- Common Stock, $0.0075 par value per share
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Jul 2026
- Price
- $42.50
- Ownership
- Direct
Form 4 holding
10%+ Owner
XOMA Royalty Corp
- Security class
- Common Stock, $0.0075 par value per share
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Jul 2026
- Price
- $42.50
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
MoonLake Immunotherapeutics
- Security class
- Class A Ordinary Shares, $0.0001 par value
- Shares / value
- 1,420,317
- Estimated value
- Report date
- 06 Jun 2024
- Price
- Ownership
- Direct
Form 4 holding
10%+ Owner
Structure Therapeutics Inc.
- Security class
- Convertible Non-Voting Ordinary Shares
- Shares / value
- 462,605
- Estimated value
- Report date
- 10 May 2023
- Price
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
10%+ Owner
Eledon Pharmaceuticals, Inc.
- Security class
- Warrants to Purchase Common Stock
- Shares / value
- 252,291
- Estimated value
- Report date
- 29 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 252,291
Form 4 holding
Other*
4D Molecular Therapeutics, Inc.
- Security class
- Pre-Funded Warrant
- Shares / value
- 240,000
- Estimated value
- Report date
- 08 Nov 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
Form 4 holding
10%+ Owner
enGene Holdings Inc.
- Security class
- Class A Common Shares
- Shares / value
- 104,257
- Estimated value
- Report date
- 31 Oct 2023
- Price
- Ownership
- Direct
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Series A Convertible Preferred Stock
- Shares / value
- 30,000
- Estimated value
- Report date
- 19 Jan 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
GLYCOMIMETICS INC
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 25,944
- Estimated value
- Report date
- 13 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Eledon Pharmaceuticals, Inc.
- Security class
- Series X1 Convertible Preferred
- Shares / value
- 7,635
- Estimated value
- Report date
- 29 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 424,169
Form 4 holding
10%+ Owner
Eledon Pharmaceuticals, Inc.
- Security class
- Series X Convertible Preferred
- Shares / value
- 346
- Estimated value
- Report date
- 29 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 19,222
Form 4 holding
Other*
PIERIS PHARMACEUTICALS, INC.
- Security class
- Series B Convertible Preferred Stock, $0.001 par value
- Shares / value
- 284
- Estimated value
- Report date
- 13 Dec 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 3,788
Form 4 holding
Other*
PIERIS PHARMACEUTICALS, INC.
- Security class
- Series C Convertible Preferred Stock, $0.001 par value
- Shares / value
- 265
- Estimated value
- Report date
- 13 Dec 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 3,535
Form 4 holding
10%+ Owner
Eledon Pharmaceuticals, Inc.
- Security class
- Warrants to Purchase Series X1 Convertible Preferred Stock
- Shares / value
- 189
- Estimated value
- Report date
- 29 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- Series X1 Convertible Preferred Stock, $0.001 par value
- Underlying amount
- 189,000
Form 4 holding
Other*
PIERIS PHARMACEUTICALS, INC.
- Security class
- Series D Convertible Preferred Stock, $0.001 par value
- Shares / value
- 163
- Estimated value
- Report date
- 13 Dec 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 2,174
Form 4 holding
Other*
PIERIS PHARMACEUTICALS, INC.
- Security class
- Series E Convertible Preferred Stock, $0.001 par value
- Shares / value
- 161
- Estimated value
- Report date
- 13 Dec 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 2,148
Form 4 holding
Other*
PIERIS PHARMACEUTICALS, INC.
- Security class
- Series A Convertible Preferred Stock, $0.001 par value
- Shares / value
- 85
- Estimated value
- Report date
- 13 Dec 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, $0.001 par value
- Underlying amount
- 1,133
Form 4 holding
Director, Other*, 10%+ Owner
CTI BIOPHARMA CORP
- Security class
- Common Stock, par value $0.001
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2023
- Price
- $9.10
- Ownership
- Direct
Form 4 holding
Director, Other*, 10%+ Owner
CTI BIOPHARMA CORP
- Security class
- Common Stock, par value $0.001
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2023
- Price
- $9.10
- Ownership
- Indirect
Form 4 holding
Director, Other*, 10%+ Owner
CTI BIOPHARMA CORP
- Security class
- Series X1 Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001
- Underlying amount
Form 4 holding
Director, Other*, 10%+ Owner
CTI BIOPHARMA CORP
- Security class
- Series X Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001
- Underlying amount
- 1,910,000
Form 4 holding
Director, Other*, 10%+ Owner
CTI BIOPHARMA CORP
- Security class
- Series X Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock, par value $0.001
- Underlying amount
- 120,000
Form 4 holding
Director, Other*, 10%+ Owner
CTI BIOPHARMA CORP
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jun 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock, par value $0.001
- Underlying amount
Form 4 holding
10%+ Owner
ESSA Pharma Inc.
- Security class
- Pre-funded Warrants
- Shares / value
- 0
- Estimated value
- Report date
- 05 Aug 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Former 10% Owner
POINT Biopharma Global Inc.
- Security class
- Common Stock, $0.0001 par value
- Shares / value
- 0
- Estimated value
- Report date
- 18 Dec 2023
- Price
- $12.45
- Ownership
- Direct
Form 4 holding
Director, Other*
Rain Oncology Inc.
- Security class
- Non-Voting Common Stock, $0.001 par value
- Shares / value
- 0
- Estimated value
- Report date
- 25 Jan 2024
- Price
- Ownership
- Direct
Form 4 holding
Director, Other*
Rain Oncology Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 26 Jan 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Structure Therapeutics Inc.
- Security class
- Ordinary Shares, $0.0001 par value per share
- Shares / value
- 0
- Estimated value
- Report date
- 10 May 2023
- Price
- Ownership
- Direct
Insider Reports Filed by BVF PARTNERS L P/IL
4
XOMA
XOMA Royalty Corp
- Report period
- 14 Jul 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 16 Jul 2026, 17:02
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 26 Jun 2026
- Transactions
- 4
- Transaction value
- -$173,665,077
- Accepted by SEC
- 26 Jun 2026, 18:48
- Role
- Director, Other*
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 24 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 25 Jun 2026, 18:58
- Role
- Director, Other*
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 18 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2026, 17:52
- Role
- Director, Other*
- Next action
- Open filing details
4
MLTX
MoonLake Immunotherapeutics
- Report period
- 17 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2026, 16:50
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Royalty Corp
- Report period
- 14 May 2026
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 18 May 2026, 17:29
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MLTX
MoonLake Immunotherapeutics
- Report period
- 31 Mar 2026
- Transactions
- 3
- Transaction value
- -$62,962,500
- Accepted by SEC
- 02 Apr 2026, 16:48
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
IMUX
IMMUNIC, INC.
- Report period
- 17 Feb 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 27 Feb 2026, 17:03
- Role
- Director, Other*
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 28 Jan 2026
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 30 Jan 2026, 18:44
- Role
- 10%+ Owner
- Next action
- Open filing details
4
EPIX
ESSA Pharma Inc.
- Report period
- 09 Oct 2025
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 14 Oct 2025, 17:33
- Role
- 10%+ Owner
- Next action
- Open filing details
4
EPIX
ESSA Pharma Inc.
- Report period
- 05 Aug 2025
- Transactions
- 9
- Transaction value
- -$0.9524
- Accepted by SEC
- 07 Aug 2025, 16:36
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 25 Jun 2025
- Transactions
- 4
- Transaction value
- +$13,955,348
- Accepted by SEC
- 01 Jul 2025, 18:41
- Role
- Director, Other*
- Next action
- Open filing details
4
GLYC
GLYCOMIMETICS INC
- Report period
- 13 Jun 2025
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2025, 18:53
- Role
- 10%+ Owner
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 11 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2025, 18:23
- Role
- Director, Other*
- Next action
- Open filing details
4
MLTX
MoonLake Immunotherapeutics
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2025, 19:16
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Royalty Corp
- Report period
- 16 May 2025
- Transactions
- 2
- Transaction value
- -$10,642,793
- Accepted by SEC
- 20 May 2025, 18:56
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALLK
Allakos Inc.
- Report period
- 15 May 2025
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 19 May 2025, 18:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Royalty Corp
- Report period
- 24 Jan 2025
- Transactions
- 4
- Transaction value
- -$16,983,714
- Accepted by SEC
- 28 Jan 2025, 17:23
- Role
- 10%+ Owner
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 10 Jan 2025
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 14 Jan 2025, 18:38
- Role
- Director, Other*
- Next action
- Open filing details
4
PVLA
PALVELLA THERAPEUTICS, INC.
- Report period
- 13 Dec 2024
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 17 Dec 2024, 17:44
- Role
- Other*
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 04 Dec 2024
- Transactions
- 9
- Transaction value
- +$22,383,570
- Accepted by SEC
- 04 Dec 2024, 19:55
- Role
- Director, Other*
- Next action
- Open filing details
4
FDMT
4D Molecular Therapeutics, Inc.
- Report period
- 08 Nov 2024
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 13 Nov 2024, 16:33
- Role
- Other*
- Next action
- Open filing details
4
THRD
Third Harmonic Bio, Inc.
- Report period
- 29 Oct 2024
- Transactions
- 3
- Transaction value
- -$14,300,000
- Accepted by SEC
- 31 Oct 2024, 17:53
- Role
- Other*
- Next action
- Open filing details
4
ELDN
Eledon Pharmaceuticals, Inc.
- Report period
- 29 Oct 2024
- Transactions
- 3
- Transaction value
- +$17,349,349
- Accepted by SEC
- 31 Oct 2024, 17:52
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MLTX
MoonLake Immunotherapeutics
- Report period
- 04 Oct 2024
- Transactions
- 3
- Transaction value
- -$100,003,200
- Accepted by SEC
- 08 Oct 2024, 18:50
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 20 Aug 2024
- Transactions
- 2
- Transaction value
- +$14,600,200
- Accepted by SEC
- 22 Aug 2024, 17:06
- Role
- Director, Other*
- Next action
- Open filing details
3
FDMT
4D Molecular Therapeutics, Inc.
- Report period
- 22 Jul 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 01 Aug 2024, 16:06
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 18 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 28 Jun 2024, 17:05
- Role
- Director, Other*
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 14 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2024, 17:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MLTX
MoonLake Immunotherapeutics
- Report period
- 06 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2024, 17:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ELDN
Eledon Pharmaceuticals, Inc.
- Report period
- 09 May 2024
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 13 May 2024, 17:04
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Rain Oncology Inc.
- Report period
- 25 Jan 2024
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 29 Jan 2024, 20:40
- Role
- Director, Other*
- Next action
- Open filing details
3
ALLK
Allakos Inc.
- Report period
- 16 Jan 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 26 Jan 2024, 17:15
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 05 Jan 2024
- Transactions
- 3
- Transaction value
- +$24,720,006
- Accepted by SEC
- 09 Jan 2024, 16:49
- Role
- Director, Other*
- Next action
- Open filing details
4
POINT Biopharma Global Inc.
- Report period
- 18 Dec 2023
- Transactions
- 3
- Transaction value
- -$213,657,911
- Accepted by SEC
- 20 Dec 2023, 18:09
- Role
- Former 10% Owner
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 15 Nov 2023
- Transactions
- 6
- Transaction value
- +$6,249,889
- Accepted by SEC
- 17 Nov 2023, 16:54
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 02 Nov 2023
- Transactions
- 6
- Transaction value
- +$5,301,325
- Accepted by SEC
- 06 Nov 2023, 18:07
- Role
- Director, Other*
- Next action
- Open filing details
3
POINT Biopharma Global Inc.
- Report period
- 02 Nov 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 06 Nov 2023, 15:35
- Role
- 10%+ Owner
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 02 Nov 2023
- Transactions
- 3
- Transaction value
- +$2,821,352
- Accepted by SEC
- 03 Nov 2023, 17:37
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ENGN
enGene Holdings Inc.
- Report period
- 31 Oct 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 Nov 2023, 16:48
- Role
- 10%+ Owner
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 12 Sep 2023
- Transactions
- 4
- Transaction value
- +$14,818,371
- Accepted by SEC
- 14 Sep 2023, 16:25
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CTI BIOPHARMA CORP
- Report period
- 26 Jun 2023
- Transactions
- 18
- Transaction value
- -$80,591,056
- Accepted by SEC
- 28 Jun 2023, 18:26
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 16 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2023, 19:14
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 15 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 17:55
- Role
- Director, Other*
- Next action
- Open filing details
4
MLTX
MoonLake Immunotherapeutics
- Report period
- 08 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 21:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Corp
- Report period
- 17 May 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 May 2023, 17:03
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
3
PVLA
PIERIS PHARMACEUTICALS, INC.
- Report period
- 11 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 22 May 2023, 17:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GPCR
Structure Therapeutics Inc.
- Report period
- 10 May 2023
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 12 May 2023, 20:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ELDN
Eledon Pharmaceuticals, Inc.
- Report period
- 05 May 2023
- Transactions
- 9
- Transaction value
- $0
- Accepted by SEC
- 09 May 2023, 20:25
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CTI BIOPHARMA CORP
- Report period
- 05 Apr 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Apr 2023, 17:00
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
3
GPCR
Structure Therapeutics Inc.
- Report period
- 03 Feb 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 Feb 2023, 19:05
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CGEM
Cullinan Oncology, Inc.
- Report period
- 19 Jan 2023
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 19 Jan 2023, 17:30
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 11 Jan 2023
- Transactions
- 4
- Transaction value
- +$1,251,191
- Accepted by SEC
- 13 Jan 2023, 16:08
- Role
- Director, Other*
- Next action
- Open filing details
4
XOMA
XOMA Corp
- Report period
- 05 Jan 2023
- Transactions
- 4
- Transaction value
- +$420,737
- Accepted by SEC
- 09 Jan 2023, 16:44
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
THRD
Third Harmonic Bio, Inc.
- Report period
- 20 Dec 2022
- Transactions
- 3
- Transaction value
- +$879,499
- Accepted by SEC
- 22 Dec 2022, 17:49
- Role
- 10%+ Owner
- Next action
- Open filing details
3
THRD
Third Harmonic Bio, Inc.
- Report period
- 19 Dec 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 22 Dec 2022, 17:47
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 08 Nov 2022
- Transactions
- 3
- Transaction value
- +$9,971,387
- Accepted by SEC
- 10 Nov 2022, 17:31
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Corp
- Report period
- 23 Sep 2022
- Transactions
- 6
- Transaction value
- +$409,309
- Accepted by SEC
- 27 Sep 2022, 19:22
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Corp
- Report period
- 14 Sep 2022
- Transactions
- 4
- Transaction value
- +$990,718
- Accepted by SEC
- 16 Sep 2022, 18:30
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 22 Aug 2022
- Transactions
- 3
- Transaction value
- +$14,183,650
- Accepted by SEC
- 23 Aug 2022, 17:35
- Role
- Director, Other*
- Next action
- Open filing details
4
CTI BIOPHARMA CORP
- Report period
- 09 Aug 2022
- Transactions
- 12
- Transaction value
- -$52,020,000
- Accepted by SEC
- 11 Aug 2022, 17:52
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
3
EPIX
ESSA Pharma Inc.
- Report period
- 11 Jul 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 21 Jul 2022, 19:26
- Role
- 10%+ Owner
- Next action
- Open filing details
3
FDMT
4D Molecular Therapeutics, Inc.
- Report period
- 16 Jun 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2022, 17:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 15 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2022, 19:20
- Role
- Director, Other*
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 13 Jun 2022
- Transactions
- 3
- Transaction value
- +$1,898,820
- Accepted by SEC
- 15 Jun 2022, 18:15
- Role
- 10%+ Owner
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 10 Jun 2022
- Transactions
- 2
- Transaction value
- +$806,900
- Accepted by SEC
- 14 Jun 2022, 16:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 02 Jun 2022
- Transactions
- 9
- Transaction value
- +$21,859,329
- Accepted by SEC
- 06 Jun 2022, 18:14
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CGEM
Cullinan Oncology, Inc.
- Report period
- 01 Jun 2022
- Transactions
- 3
- Transaction value
- +$8,264,905
- Accepted by SEC
- 03 Jun 2022, 18:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 26 May 2022
- Transactions
- 6
- Transaction value
- +$4,150,321
- Accepted by SEC
- 31 May 2022, 19:50
- Role
- Director, Other*
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 20 May 2022
- Transactions
- 3
- Transaction value
- +$141,394
- Accepted by SEC
- 24 May 2022, 20:09
- Role
- Director, Other*
- Next action
- Open filing details
4
XOMA
XOMA Corp
- Report period
- 18 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 May 2022, 19:18
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 18 May 2022
- Transactions
- 3
- Transaction value
- +$3,570,000
- Accepted by SEC
- 20 May 2022, 18:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CGEM
Cullinan Oncology, Inc.
- Report period
- 12 May 2022
- Transactions
- 5
- Transaction value
- +$10,063,936
- Accepted by SEC
- 16 May 2022, 19:34
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 05 May 2022
- Transactions
- 6
- Transaction value
- +$4,865,365
- Accepted by SEC
- 09 May 2022, 19:20
- Role
- Director, Other*
- Next action
- Open filing details
3
MLTX
MoonLake Immunotherapeutics
- Report period
- 05 Apr 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 15 Apr 2022, 17:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CGEM
Cullinan Oncology, Inc.
- Report period
- 01 Apr 2022
- Transactions
- 2
- Transaction value
- +$2,966,972
- Accepted by SEC
- 05 Apr 2022, 18:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CTI BIOPHARMA CORP
- Report period
- 09 Mar 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Mar 2022, 20:03
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 27 Jan 2022
- Transactions
- 4
- Transaction value
- +$5,076,473
- Accepted by SEC
- 31 Jan 2022, 18:44
- Role
- Director, Other*
- Next action
- Open filing details
3
VSTM
Verastem, Inc.
- Report period
- 25 Jan 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 07 Feb 2022, 19:23
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 24 Jan 2022
- Transactions
- 2
- Transaction value
- +$10,300,637
- Accepted by SEC
- 26 Jan 2022, 18:43
- Role
- Director, Other*
- Next action
- Open filing details
3
ELDN
Eledon Pharmaceuticals, Inc.
- Report period
- 20 Jan 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 31 Jan 2022, 19:52
- Role
- 10%+ Owner
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 19 Jan 2022
- Transactions
- 3
- Transaction value
- +$14,071,250
- Accepted by SEC
- 21 Jan 2022, 16:12
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 06 Jan 2022
- Transactions
- 4
- Transaction value
- +$6,692,638
- Accepted by SEC
- 10 Jan 2022, 17:03
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
3
CGEM
Cullinan Oncology, Inc.
- Report period
- 31 Dec 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 10 Jan 2022, 16:40
- Role
- 10%+ Owner
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 30 Nov 2021
- Transactions
- 3
- Transaction value
- +$6,945,770
- Accepted by SEC
- 02 Dec 2021, 19:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
RPTX
Repare Therapeutics Inc.
- Report period
- 28 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 08 Nov 2021, 17:12
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MRUS
Merus N.V.
- Report period
- 07 Oct 2021
- Transactions
- 6
- Transaction value
- -$31,222,474
- Accepted by SEC
- 08 Oct 2021, 21:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 21 Sep 2021
- Transactions
- 3
- Transaction value
- +$153,829
- Accepted by SEC
- 23 Sep 2021, 20:05
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 13 Sep 2021
- Transactions
- 3
- Transaction value
- +$6,468,516
- Accepted by SEC
- 15 Sep 2021, 17:23
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
MRUS
Merus N.V.
- Report period
- 02 Jul 2021
- Transactions
- 3
- Transaction value
- -$45,359,956
- Accepted by SEC
- 07 Jul 2021, 16:49
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 01 Jul 2021
- Transactions
- 6
- Transaction value
- +$9,078,692
- Accepted by SEC
- 06 Jul 2021, 19:34
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 01 Jul 2021
- Transactions
- 3
- Transaction value
- +$25,575,802
- Accepted by SEC
- 06 Jul 2021, 18:40
- Role
- Director, Other*
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 16 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2021, 16:19
- Role
- Director, Other*
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 21 May 2021
- Transactions
- 6
- Transaction value
- +$1,966,334
- Accepted by SEC
- 25 May 2021, 20:31
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
XOMA
XOMA Corp
- Report period
- 19 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 May 2021, 18:48
- Role
- Director, Other*, 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 18 May 2021
- Transactions
- 6
- Transaction value
- +$3,457,720
- Accepted by SEC
- 20 May 2021, 19:18
- Role
- Director, Other*
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 13 May 2021
- Transactions
- 3
- Transaction value
- +$827,167
- Accepted by SEC
- 17 May 2021, 20:43
- Role
- Director, Other*
- Next action
- Open filing details
4/A
Rain Therapeutics Inc.
- Report period
- 23 Apr 2021
- Transactions
- 9
- Transaction value
- +$19,103,380
- Accepted by SEC
- 17 May 2021, 20:39
- Role
- Director, Other*
- Next action
- Open filing details
4
OLMA
Olema Pharmaceuticals, Inc.
- Report period
- 31 Mar 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 26 May 2021, 21:37
- Role
- Director, 10%+ Owner
- Next action
- Open filing details